Even though EPO metabolites can reduce cholesterol and LDL levels, n-6 metabolites (considerably DGLA and AA) deficiency is another risk factor for CHD and low levels of LA, explain it [75]. The gene discussed is EPO; the disease is coronary artery disorder.